GSK Licenses Shigella Vaccine Candidate

By Nina Kienle

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International.

The U.K. pharma company on Thursday said the agreement paves the way for the development and potential distribution of the vaccine in low- and middle-income countries where Shigella, the leading bacterial cause of diarrhea, poses a significant health threat to children under five.

The Phase 1 clinical trial demonstrated promising results and confirmed the achievement of preset immunogenicity success criteria, GSK said.

The vaccine uses GMMA technology--Generalized Modules for Membrane Antigens--a novel platform based on bacterial outer membranes for delivery of the O Antigen to the immune system, it said.

Following the technology transfer, GSK will collaborate with BBIL on its design of the Phase 3 trial and support BBIL's efforts to secure external funding, the company said.

Write to Nina Kienle at [e-mail]

(END) Dow Jones Newswires

06-12-25 0503ET